General Information
Revision date
2019-09-11
Product name
Azacitidine for Injection 100 mg/vial
CAS No.
320-67-2
Manufacturer Name
Accord Healthcare Pty Ltd
Icons in SDS
Company Information
company name
Accord Healthcare Pty Ltd
GHS Information
Signal word
Danger
Hazard Codes
Hazard statements (CLP)
H302, H341, H350, H360FD, H372, H400, H410
Hazard statements
Code
Statements
H302
Harmful if swallowed
H341
Suspected of causing genetic defects
H350
May cause cancer
H360FD
May damage fertility. May damage the unborn child.
H372
Causes damage to organs through prolonged or repeated exposure
H400
Very toxic to aquatic life
H410
Very toxic to aquatic life with long lasting effects
Section 2
SECTION 2: Hazards identification
Globally Harmonized System [GHS]: Carcinogenic - Category 1B Germ Cell Mutagenicity - Category 2 Reproductive Toxicity - Category 1B Acute toxicity - oral - Category 4 Specific Target Organ - Category 1 Toxicity (repeated exposure) Aquatic toxicity (acute) - Category 1 Aquatic toxicity (chronic) - Category 1
Signal word
Danger
Hazard statements
H302 - Harmful if swallowed. H341 - Suspected of causing genetic defects. H350 - May cause cancer. H360FD - May damage fertility. May damage the unborn child. H372 - Causes damage to hematological and gastrointestinal systems through prolonged or repeated exposure. H400 - Very toxic to aquatic life. H410 - Very toxic to aquatic life with long-lasting effects.
Precautionary statements
P201 - Obtain special instructions before use. P202 - Do not handle until all safety precautions have been read and understood. P260 - Do not breathe dust. P264 - Wash hands thoroughly after handling. P270 - Do not eat, drink or smoke when using this product. P273 - Avoid release to the environment. P281 - Use personal protective equipment as required. P308 + P313 - If exposed or concerned: get medical advice/attention. P301+P312 - IF SWALLOWED: Call a Poison Center or doctor/physician if you feel unwell. P330 - Rinse mouth. P391 - Collect spillage P405 - Store locked up. P501 - Dispose of contents/container to location in accordance with local/regional/national/international regulations. P280 - Wear protective gloves/eye protection/face protection. P308 + P313 - IF exposed or concerned: get medical advice/attention.
2.3 Other hazards
The most commonly occurring adverse effects with therapeutic use include hematological toxicity (e.g., thrombocytopenia, anemia, neutropenia), fever, gastrointestinal effects (e.g., nausea, vomiting, diarrhea, constipation), fatigue, injection site erythema, ecchymosis (skin discoloration caused by escape of blood into tissues from ruptured blood vessels). Other effects may include hypotension, shortness of breath, liver/kidney toxicity and electrolyte abnormalities. Post marketing reports of interstitial lung disease and tumor lysis syndrome may also be azacitidine-related. Note: This mixture is classified as hazardous under GHS as implemented by Regulation EC No 1272/2008 (EU CLP), WHMIS 2015 (Health Canada), and Hazard Communication Standard No. 1910.1200 (US OSHA). See Section 16 for full text of EU and GHS classifications.